#CMSC17 – Celgene’s Investigational Therapy Ozanimod Safe, Effective in Treating Relapsing MS, Clinical Trial Finds
Long-term treatment for up to 12o weeks, with theĀ investigational drug Ozanimod (RPC-1063), found to be effective and safe in patients with relapsing multiple sclerosis (MS) who participated in the RADIANCE clinical trial. Celgene, Ozanimod’s developer, presented the study, āEfficacy and Safety of Ozanimod in the Blinded Extension (120…